Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine

被引：0

作者：

Garcia-Manero, Guillermo ^{[1
]}

McCloskey, James ^{[2
]}

Scott, Bart L. ^{[3
]}

Griffiths, Elizabeth A. ^{[4
]}

Kiner-Strachan, Bonnie ^{[5
]}

Roboz, Gail J. ^{[6
,7
]}

Meyer, Janelle ^{[8
]}

Chan, Winny ^{[9
]}

Sano, Yuri ^{[9
]}

Oganesian, Aram ^{[9
]}

Keer, Harold K. ^{[9
]}

Savona, Michael R. ^{[10
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Hackensack Med Ctr, John Thuerer Canc Ctr, Hackensack, NJ USA

[3] Fred Hutchinson Canc Ctr, Seattle, WA USA

[4] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[6] Weill Cornell Med, New York, NY USA

[7] NewYork Presbyterian Hosp, New York, NY USA

[8] Oregon Oncol Specialists, Salem, OR USA

[9] Taiho Oncol Inc, Pleasanton, CA USA

[10] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

MDS; ASTX030; azacitidine; cedazuridine; oral hypomethylating agents; myelodysplastic syndromes; CMML;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-773

引用

页码：S406 / S407

页数：2

共 42 条